OSE Immunotherapeutics Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in a Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.